

CURRICULUM VITAE - MEMORIU DE ACTIVITATE

Nume: GRIGORESCU

Prenume: ALEXANDRU CĂLIN

POZIȚIA PREZENTĂ:

(Spitalul Clinic de Nefrologie "Dr. Carol Davila" Bucuresti)

Cercetător științific gradul I prin ordinul MECTI nr. 4506, 22 iulie 2010

Doctor abilitat, UMF Carol Davila, Ordin MS 2014

Doctor în științe medicale UMF Carol Davila 2002

Medic primar Oncologie Medicală

Competență bronhologie

Competență îngrijiri paliative

Fost Reprezentant al României în Grupul de Paliatie al Societății Europene de Oncologie Medicală(ESMO-Designed Centers)

Fost reprezentant național ESMO

Fost Reprezentant național în Societatea Internațională de geriatrie oncologică

Membru al Societății Americane de Oncologie Clinică

Membru al Societății Internaționale de Studiu al Cancerului Bronhopulmonar (IASLC)

Membru al Societății Europene de Îngrijiri Paliative

Fost presedinte executiv al Societății Naționale de Oncologie Medicală din România (SNOMR)

Membru în Advisory Board al revistei „FramingHam on lung cancer”

Redactor șef al revistei „Oncolog Hematolog”

Peer reviewer în F1000

Peer reviewer „Asia Pacific Journal of Oncology”.

Peer reviewer al revistei „Translational Oncology”

Expert al Comisiei Europene în Programul de oncologie HORIZON 2020,

Fost Șef de secție „Oncologie Medicală 2”IOB

Șef compartiment oncologie Sp Clinic de Nefrologie „Dr. Carol Davila”

Coordonator în Sp Clinic de Nefrologie Dr. Carol Davila al „Centrului desemnat de ESMO pentru integrarea Oncologiei Medicale cu Îngrijirile Paliative”.

Membru de onoare al Academiei de Științe Medicale din România.

EDUCAȚIE:

1974 Liceul "Gheorghe Lazar", București

1981 Absolvent al Facultății de Medicină Generală "Carol Davila"– București

- 1981 1984 Stagiatură: Spital “Ion Cantacuzino”- București
- 1984 1988 Medic de medicină generală: Jud. Bacău
- 1988 Admis prin concurs pentru secundariat în Oncologie și chimioterapie (Oncologie Medicală) la Institutul Oncologic București.
- 1991 Specialist Oncologie Medicală
- 1991 Competență bronhologie
- 1995 Medic primar Oncologie Medicală
- 2002 Susținerea tezei de doctorat –iulie- București
- 2005 Competență îngrijiri paliative

STAGII , CURSURI, EXAMENE

- 1990 Stagiul de bronhologie Institutul național de pneumologie « Marius Nasta »
- 1991 Examen de specialist în Oncologie Medicală
1991. Obținerea titlului de cercetător în oncologia clinică
- 1993 (Aprilie.- Junie.) Stagiul practic de oncologie medicală și bronhoscopie intervențională la Spitalul Laennec (Nantes – France)
- 1994 Curs de “Biologie moleculară pentru medicii clinicieni” (Ascona Switzerland)
- 1995 Admis pentru doctorat cu tema “Cancerul Bronhopulmonar fără celule mici avansat”. Institutul de Pneumoftiziologie Marius Nasta București, coordonator științific Prf.Dr. Emil Corlan UMF ”Carol Davila ”
- 1995, 20-26 iunie, stagiul de curieterapie endobronșică, Hôpital Guillaume et René Laënnec (Nantes, Franța).
- 1997 Curs de bună practică clinică în Oncologia Medicală “Good Clinical Practice (GSP) in Medical Oncology” – Copenhaga, Danemarca, 20-25 octombrie .
- 1998 **Examen de promovare ca Cercetător științific principal gradul III.(Academia Romana de Medicina)**
- 1998 Curs ESMO: “Reading, Writing and Randomised Trials” Budapesta, 28-31 octombrie.
- 1999-2000 Curs româno francez de psihooncologie – București- Diplomă de absolvire, referat absolvire.
- 2001 “Oncology Speakers Training Workshop Meeting” – Praga 6-8 septembrie
- 2002 **Susținerea tezei de doctorat, iulie Bucuresti**

2003 Examen pentru titlul de cercetător științific gradul II. - Validare nr. 1201/18 02 2003(*Academia Romana de Medicina*)

2004 Advanced course in thoracic tumors" Rhodes /Greece iunie 16 /19 iunie.

2006 Community in practice,(Apdatarea cunoștințelor în diagnosticul și tratamentul cancerului bronhopulmonar) – Hamburg, octombrie 2006

2009 ESMO grant în îngrijiri paliative - St. Galen Elveția

2009 Curs de bună practică clinică- St Galen –Elveția

2010- Examen cercetător științific gradul I, WIRA -SA

PARTICIPIRI LA CONFERINȚE ȘI CONGRESE (vezi anexa)

ACTIVITĂȚI PROFESIONALE DIDACTICE SI DE CERCETARE

1991 Organizarea laboratorului de endoscopie bronșică din Institutul Oncologic București

1996 Membru fondator al “Central Eastern European Oncology Group” condus de Prof. Heine H. Hansen, Danemarca.

1996-2005 **Reprezentant al Romaniei în “ESMO (European Society for Medical Oncology) Central Eastern European Task- Force”**. Grup cu următoarele atribuții:
- identificarea mijloacelor care să ducă la recunoașterea Oncologiei Medicale ca specialitate de sine stătătoare,

Instruire în vederea organizării unui grup de studii clinice, concretizată în înființarea :
“**Central Eastern European Oncology Group**”,

Stabilirea unor legături între ESMO și societățile naționale de oncologie medicală.

Activități educationale si de cercetare in cadrul Grupului tarilor din estul Europei organizat de ESMO sub conducerea profesorului Heine Hansen presedintele ESMO. Activitate desfasurata intre 1995 si 2005. In cadrul grupului s-au pus bazele organizarii ulterioare a ESMO: realizarea ghidurilor terapeutice, cursurile internationale, studiul efectuării dizainul studiilor clinice. Grupul a propus ESMO programul 5x5x5. Acest program a reprezentat sustinerea a 5 cursuri cu 5 tematici diferite in 5 tari diferite. Dupa fiecare curs pe care l-am organizat in Romania am publicat cate o carte la Editura UMF Carol Davila cu tematica de curs.

La sfarsitul activitatii acestui grup (ESMO Central Easter Oncology Task Force) am fost desemnat sa prezint in sinteza activitatea grupului la Congresul ESMO de la Istambul in 2005. Activitatea in acest grup se incadreaza in activitatea sustinuta de Academia de stiinte medicale. De asemenea activitatea pe care am avut-o 10 ani ca reprezentant in Societatea Internationala de Geriatri Oncologica, activitate care a promovat infiintarea unei specializari in geriatrie oncologica se inscrie in activitatile promovate de Academia de Stiinte Medicale: “Fondarea unor specialități și discipline noi și/sau fondarea unor instituții medicale, de învățământ medical, asociații sau fundații care sprijină pacienții, care apără interesele corpului medical, care susțin, organizează și desfășoară, în condițiile legii, activitate didactică, științifică în domeniul medical sau care promovează misiuni ce urmăresc dezvoltarea medicinei, a cercetării medicale fundamentale și clinice”;

In cadrul activităților din "ESMO Designed Centers for Integration of Medical Oncology with Palliative Care" am obținut recunoașterea Institutului Oncologic București ca Centru Desemnat ESMO al cărui Coordonator sunt. Centrul figurează pe sit-ul ESMO: <https://www.esmo.org/Patients/Designated-Centres-of-Integrated-Oncology-and-Palliative-Care/Institute-of-Oncology-Prof.-Dr.-Alexandru-Trestioreanu-Romania>.

Ulterior figurand si Spitalul Clinic de Nefrologie „dr. Carol Davila”.

În conformitate cu Ordinul MS 942 /2017 am fost numit Responsabil Național pentru Cursul de Specializare al asistenților medicali în Specialitatea de Oncologie Medicală, prima inițiativă de acest gen din România. În consecință am elaborat curricula de pregătire în Specialitate și am recomandat alte centre unde am reușit să creez echipe (Iași, Timișoara, Constanța).

- În cadrul activităților ca reprezentant Național în Societatea de Geriatrie Oncologică am organizat primul curs internațional de geriatrie oncologică din România.

1998 Coorganizator și lector al cursului Societății Europene de Oncologie Medicală (ESMO): "Cytostatic agents delivery and toxicity", Sinaia- Romania.

1996-2005 **Reprezentant al României în "ESMO (European Society for Medical Oncology) Central Eastern European Task- Force"**. Grup cu următoarele atribuții:

- identificarea mijloacelor care să ducă la recunoașterea Oncologiei Medicale ca specialitate de sine stătătoare,
- insruire în vederea organizării unui grup de studii clinice, concretizată în înființarea : "Central Eastern European Oncology Group",
- activitate de inițiere în organizarea de simpozioane, cursuri de oncologie medicală și nursing oncologic, concretizată în organizarea a două cursuri sub egida ESMO în România,
- stabilirea unor legături între ESMO și societățile naționale de oncologie medicală.

1999 **Desemnat Reprezentant Național al României în Societatea Europeană de Oncologie Medicală (Primul Reprezentant Național al României în această societate)**

2000

2000 **Membru fondator al ESMO- PCWG (Paliative Care Working Group)**

2001 Președinte de curs și lector pentru ESMO course "Reading Writing Clinical Trials"- Sinaia, Romania (5-7septembrie)

2002 **Copreședinte al sesiunii de psihooncologie a Congresului Societății Europene de oncologie medicală.(Nice /Franța 18-22 Octombrie).**

2003 **Membru în secretariatul "Central European Lung Cancer Conference" Viena, 1- 4 septembrie.**

2001 Membru în comitetul de organizare al cursurilor ESMO din Programul educațional : « 5x5x5 »

2010 Obținerea pentru IOB a titlului de “Centru desemnat de ESMO pentru integrarea Oncologiei Medicale cu Îngrijirile Paliative” pentru Institutul Oncologic Buciurești

2009 – 2019 :Reprezentant Național în Societatea Internațională de Geriatrie Oncologică (SIOG)www.siog.otg

2012-2013 Membru al grupului de prevenție și diagnostic precoce al Societății Internaționale de studiu al Cancerului Pulmonar (IASLC)

2013 – prezent: Membru al Societății F1000, ca post peer review- er al publicațiilor de oncologie, gerontooncologie, paliative.

2017 – 2024 Membru al grupului ESMO “ESMO Designed Center Group”

CERCETARE:

1. Grant Spitalul Laennek (Nantes – France) cercetare observationala oncologie toracica 1993
2. Coinvestigator în “Central Eastern European Oncology Group” (1998).
(studiul clinic cu monitorizare internațională: “5-Fluorouracilul în bolus sau perfuzie de scurtă durată în cancerul de colon avansat” în cadrul
3. 2001 Director proiect de cercetare sub egida Academiei de Științe Medicale cu titlul: Studiu clinic controlat de faza a II-a privind tratamentul asociat chimio-radioterapic față de chimio-radioterapia plus curieterapia endobronșică în cancerul bronho-pulmonar inoperabil cu obstrucție bronșică” care face obiectul contractului nr. 048/22.10.2001 încheiat între Academia de Științe Medicale – UCPN VIASAN și Institutul Oncologic Prof.dr. Alex.Trestioreanu București,
4. Elaborare design și Investigator principal în studiul național “Gemzar plus vinorelbina urmat de gemzar plus ifosfamidă față de gemzar plus cisplatin în cancerul bronhopulmonar fără cellule mici avansat
5. Coordonator program IOB în grantul obținut de la Academia Medicală: “Tehnologie Avansata De Tratament A Pleureziilor Maligne Prin Termochimioterapie Intrapleurala”, <H-Tech Tcip>, Nr 3, 84, 2006
6. Coordonator pentru Romania al proiectelor de cercetare în cadrul ESMO-PCWG 2000-2012.
7. Director proiect cercetare WIRA-SA 2010
8. 2010 Director proiect cercetare Wira SA: “Ponderea apariției tumorilor canceroase în cadrul colectivelor de muncă în centralele electrice, în special de congenerare din deșeuri”
9. Grant ESMO cercetare în îngrijiri paliative 2009, St. Galen –Elveția
10. Investigator in proiectul de cercetare in ingrijiri paliative Elveția –Romania.2012- 2015.

>

Studii clinice(selectie) :

Programul / Proiectul	funcția	Perioada
Phaze II study: Gemcitabine monotherapy	coinvestigator	1997 -1999

in advanced non small lung cancer, Elly Lilly 1997		
5 Fluorouracil in shot perfusion versus bolus administration , Cenrtal Eastern European Oncolgy Group 1998	nvestigator principal	1998- 1999
Phaze III international study of oral Topotecan in second line of advanced small cell lung cancer, Glaxo-Smithkline 2001	nvestiogator principal	2001-2003
Studiu de faza a II-a, Gemcitabina plus cisplatin versus gemcitabina plus vinorelbina urmata de gemcitabina plus fosfamida in administrare secventiala 2002, Elly Lilly	nvestigator principal	2002 -2004
Studiul international ChEST, Preoperator chemotherapy in Early stage non small cell lung cancer, Elly Lilly	nvestigator principal	2003-2005
Studiul de faza a II-a, randomizat privind administrarea de extract de ecidiva pentru ameliorarea durerii în cancerul avansat. 2004	nvestigator principal	2004
Studiul international de faza a IV-a privind chimioterapia de faza a II-a cu tarceva., Roche.	nvestigator principal	2005-prezent
Studiu clinic controlat de faza a II-a privind tratamentul asociat chimio-radioterapic fata de chimio-radioterapia plus curieterapia endobronscica în cancerul bronho-pulmonar inoperabil cu obstructie bronsica care face obiectul contractului nr. 048/22.10.2001 încheiat între Academia de stiinte Medicale – UCPN VIASAN si Institutul Oncologic Prof.dr. Alex.Trestioreanu Bucuresti	Director de proiect	2002- 2004
Studiul international de faza a II-a privind hormonoterapia cu inhibitori selectivi de aromatază în cancerul mamar ecidivate sau metastatic. (2005).Intarcia –USA	nvestigator principal	2005-2006
Coinvestigator în studiul privind administrarea de anticorpi monoclonali (removab) pacientilor cu ascita neoplazică refractară la citostatice (2005),Fressenius –Germania	Subinvestigator	2005-2007
Tehnologie avansata de tratament a pleureziilor maligne prin termochimioterapie intrapleurala, Nr. 3 / 84 / oct. 2006	Coordonator proiect parteneriat BOB	2006- 2009

A Multi-center , Randomized , double-blind , Placebo-controlled, Phase 3 Study of Single –agent Tarceva following Complete Tumor Resection and with or without Adjuvant chemotherapy in patients with Stage IB-III A Non –Small Cell Lung Carcinoma who have EGFR – Positive Tumors	investigator principal	2007-2008
A randomized withdrawal, active –and placebo –controlled , double –blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor- related pain. – Grunenthal	investigator principal	2007-2008
Phase 2, randomized, open label, multicenter study of intradermal IMA 901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease- Immatics	investigator principal	2007-2008
A Randomized Double blind Multicenter study of Denosumab Compared with Zoledronic Acid in the Treatment of Bone Metastasis in Men with Hormon – refractory prostate cancer.	investigator principal	2008+2009
Studiu nonintervențional Eligard 7,5 mg și 22,5 mg pentru tratamentul cancerului avansat de prostată hormonodependent	investigator principal	2009
Studiul DMS32212R - cancer bronhopulmonar avansat	investigator principal	2009-2010
Studiul ML 20951, Tarceva (studiu original la propunerea investigatorului principal)	investigator principal	2009-2010
Phase 2 randomized study of carboplatin paclitaxel with or without CS -7017 in chemotherapy –naive subjects with metastatic non-small cell lung cancer, CS7017-A+U202	investigator principal	2010-2011
Studiul IUNO, (Erlotinib in cancerul bronhopulmonar metastatic)	investigator principal	2012-2013
Studiul MSD “Palonosetronul in terapia antiemetică generată de citostatice cu efect hiperemetic mediu~	investigator principal	2015-2014
Studiul Grunenthal: Cerebropradol-ul versus sulfatul de morfina in durerea medie și severă din cancer	investigator principal	2014-2015

Studiul Academic sponsorizat de autoritatea academica elvetiana IZERZO	Coordonator al echipei din Bucuresti	2013-2015
Studiul Flaura in cancerul pulmonar avansat cu rezistenta la EGFR	Investigator principal	2015-2016
Studiul Merck – Avelumab versus chimioterapie in Cancerul pulmonar fara celule mici avansat, metastatic	Investigator principal	2017-2019
Studiul NERO- Utilizarea protocoalelor antiemetice in chimioterapia cu citostatice inalt si moderat hiperemetice	Investigator principal	2017-2019
Studiul “Reason” Astra Zeneca: Durvalumab in SCLC	investigatot principal	2020-2023
A Phase 1a/b, Dose finding, open-label study to evaluate safety and toxicity, of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer	Investigator principal	2022-2024
A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects with Advanced Malignancies	investigator principal	2022-2024
An open label trial of BI 765063 in combination with BI 754091 (ezabelimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC)	nvestigator principal	2022-2026

EXPERIENȚA DIDACTICĂ:

1. Lector in cursul organizat de ESMO (Societatea Europeana de Oncologie Medicala) “Cytostatic agents delivery and toxicity”, Sinaia- Romania 1998. (Primul curs internațional organizat de IOB sub egida ESMO și primul curs cu traducere simultană engleză-română pentru medici oncologi și asistente).
2. Președinte de curs și lector în cursul ESMO: “Reading Writing Clinical Trials”- Sinaia, Romania (5-7septembrie 2001).

3. Co -preșdinte la sesiunea de psihooncologie din cadrul Congresului ESMO de la Nice -France 2002
4. Preșdinte de curs și lector în cursul ESMO: "Fundamentals in Medical Oncology", Sinaia 2003.
5. Preșdinte de curs ESMO și lector: "Lung cancer and Head and neck tumors " Bucharest October 2004
6. Preșdinte de curs ESMO și lector în cursul: "Gastrointestinal malignancy", București 2005.
7. Preșdinte de curs și lector în Simpozionul SIOG)societatea internațională de Geriatrie Oncologică) - SNOMR (Societatea Nationala de Oncologie Medicală din Romania), Poiana Brașov 2006.
8. Lector în cadrul "Școlii Europene de Oncologie": "Masterclass in Palliative Cancer Care", Tbilisi -Georgia, 2007.
9. Lector în Simpozionul ESMO: "Palliative and Supportive care in Medical Oncology", București 2007.
10. Lector si preșdinte de simpozion: "ASCO-SIOG-SNOMR Symposium" Poiana Brașov 2009
11. Preșdinte de simpozion și lector în Simpozionul ESMO: "Update in Medical Oncology", Poiana Brașov 2010.
12. Preșdinte simpozion și lector: "Palliative Care" în cadrul "Zilelor științifice ale IOB" București 2010.
13. Lector și preșdinte de simpzion: "New trend in Medical Oncology", ASCO-SNOMR Symposium , Poiana Brașov 2011.
14. Lector și preșdinte simpozion internațional: "Integration of Palliative Care with Medical Oncology", în cadrul "Zilelor științifice ale IOB". București 2011.
15. Coordinator și lector în "INTERNATIONAL SYMPOSIUM ASCO-SNOMR": "Lung cancer a change for new therapies", 12- 13 October 2012 Poiana Brasov – ROMANIA
16. BREAST CANCER ACTUAL KNOWLEDGE AND NEW STANDARDS TO IMPROVE SURVIVAL AND QUALITY OF LIFE, ESMO-SNOMR Symposium Coordinator: Alexandru C. Grigorescu MD, PhD, SRDI
Poiana Brasov _18-19 octmbrie 2013
17. Lector în cursul "Tratamenmtul multimodal al cancerului mamar" Congresul Național de Chirurgie – Sinaia mai 2014
18. Lector în cursul: "Tratamentul complex al cancerului de rect" Congresul Național de Chirurgie – Sinaia mai 2014
19. Curs online avizat de UMF Carol Davila Bucuresti „Terapia durerii, probleme de comiunicare in cancer”2016
20. Curs online avizat de UMF Carol Davila „Imunoterapia in cancerul bronhopulmonar”2017
- 21 Coordonator National avizat de Ministerul Sanatatii pentru cuesul de specializare a asistentelor medicale.

PREZENTARI IN MANIFESTARI STIINTIFICE:

1. Problems of bronchoscopy in diagnosis of lung cancer - Colloquium Romanian - French Pneumology, Bucharest, October 1991.
2. Evolving clinical and therapeutic aspects in carcinomatous mastitis, Grigorescu Alexander Mogoş Ion, Done {Serban, Doina Spataru Conference naţională de oncology, Craiova 8 to 9 October 1992.
3. Diagnosis and treatment of advanced lung cancer, Alexandru Grigorescu, John Mogoş, {Serban done, Dana Stănculeanu, Scientifically days of Institute of Oncology Bucharest 1993.
4. The combination of radiotherapy and chemotherapy in NSCLC. Alexandru Grigorescu, Maricica Palade, Mircea Savu, Anton Ionescu, Days radiotherapy, Bucharest May 24 to 25, 1994
5. CEA and CA125 in the diagnosis, monitoring and development of NSCLC. Alexandru Grigorescu, Eliza Mănoiu, Nicholas Stafidov, Days radiotherapy session of IOB. 26 to 27 May 1995
6. Pilot study on the use of interferon in aerosols or introduced by bronchoscopy in the treatment of obstructive endobronchial neoplastic syndrome, Alexandru Grigorescu, naţională de Oncology Conference, Poiana Brasov, 24-25 October 1996.
7. Chemotherapy versus chemotherapy associated with biphosphonates in the treatment of pain in lung cancer with bone metastases, Alexandru Grigorescu, IOB ştiinţifică anuală Session, 29-30 May 1997.
8. Polychemotherapy regimens in non small cell lung cancer, administration protocol, tolerance, toxicity. Alexandru Grigorescu, National Cancer Congress, Poiana Brasov, 1997.
9. Randomized phase II trial: chemotherapy of carboplatin plus gemcitabine versus cisplatin and vinblastine in advanced NSCLC. Alexandru Grigorescu, Nicolae Guţulescu, National Congress of Oncology, Bucharest October 14 to 16, 1999.
10. Open clinical study on the influence of chemotherapy on quality of life and survival of patients with advanced lung cancer, Alexandru Grigorescu Nicolae Guţulescu.
11. Combination chemo-radiotherapy in mediastinal compression syndrome in cancer, Alexandru Grigorescu, Xenia Bacinschi, Alin} Arle, first conferinţă naţională de medical oncology, Craiova - Căciulata 11 to 14 April 2002.

12. Ioan Popa, Alexandru Calin Grigorescu, Michael Gr Mark, Mona Marin ,Study of risk factors and survival in chronic diseases - statistical approach, Conference anniversary of the Institute of Public Health, Bucharest, June 12 to 13, 2003.

13. Grigorescu, T. Ciuleanu, Elena Firoiu, Delia Muresan, C. Davidescu, M. Ciochinaru, R. Curca, Roberta Rosca, Gabriela Teodorescu ,Sequential combination of gemcitabine plus vinorelbine followed by gemcitabine versus gemcitabine plus ifosfamide plus cisplatin in the treatment of non-small cell lung cancer stages III and IV, preliminary results of a randomized phase II study.

National Conference of Oncology, Durau, 10 - September 14, 2003, p34. T. A.

14. Doina Spataru, A. Grigorescu, Comparative study of adjuvant chemotherapy with 5 fluorouracil versus polychemotherapy in stage III gastric cancer, Scientifically days of Institute of Oncology Bucharest November 2003.

15. Continuous infusion devices used in chemotherapy of digestive malignancies. Scientifically Days of Institute of Oncology "Prof. Dr. Ion Chiricuță» 9 to 10 October 2003.

16. "Organizing a center for clinical trials," communication training sessions continue in IOB. November 2003.

17. Comunicari anuale 2004-2019 la zilele stiintifice ale Institutului Oncologic Bucuresti, Conferintele SNOMR, Conferintele Institutului Oncologic Iasi.

18. Speaker la Congresul "Cancer Science and research" 17-19 2025 Singapore

19. Lector la Conferinta "CONFER" Iasi 2025

20. Speaker la "World Congress on Future of Aging : Science Society and Sustainability" Virtually July 09-10 2025

PUBLICATII

CARTI si CAPITOLE:

1. Alexander C Grigorescu, "Breviary of diagnosis and treatment of advanced lung cancer," Ed Bacovia, Bacau 2000, p 1-172.

2. Alexander C. Grigorescu, "Breviary of diagnosis and treatment of advanced lung cancer," second edition, Ed "Cartex 2000", Bucharest 2003.p 1-192.

3. Alexandru Grigorescu, Rodica Anghel and all, Principles of clinical trials in oncology, Ed Carol Davila – Bucharest 2006, p3-235.

4. Alexandru Grigorescu: "Respiratory Problems in" ESMO Hand book of Advanced Cancer Care ", Taylor & Francis Books Ltd, 2006, P97-104

5. Alexandru Grigorescu, Heine Hansen, Rodica Anghel, and all "ESMO Head and neck course, thoracic tumors," Carol Davila - Bucharest 2006, 1-238

6. Alexandru Grigorescu, Hans Joachim Small, Rodica Anghel, and all. "ESMO course,

gastrointestinal malignancy," Ed Carol Davila, Bucharest 2007, 3-283

7. Alexandru Grigorescu, Nathan Cherny, Dana Stănculeanu and all "Palliative and supportive care in Medical Oncology" Ed Carol Davila Bucharest 2007, p3-11.p3-201

8. Alexandru Grigorescu, Medical Treatment of Advanced Lung Cancer, Editura Medicala, Bucharest 2008, p3-173

9. Alexandru Grigorescu, Lodovico Balducci, Florinel Badulescu, and all, 'Update in Medical Oncology Editura Medicala - Romania, 2011.p11-254.

10. Alexandru Grigorescu, **Management of Chemotherapy Complications in Gynecological Malignancy Treatments**, Ali Ayhan, Nicholas Reed, Murat Gultekin si Polat Dursun., Textbook of Gynaecological Oncology, " Gunes Publishing" 2016.

11. Immunotherapy in Advanced Lung Cancer Treatment, October 2018, DOI: 10.5772/intechopen.77005, In book: Lung Cancer - Strategies for Diagnosis and Treatment License [CC BY 3.0](https://creativecommons.org/licenses/by/3.0/)

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progression on platinum-based therapy ...

EB Garon, TE Ciuleanu, O Arrieta, K Prabhaskar, KN Syrigos, T Goksel, ...
The Lancet 384 (9944), 665-673

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, r small-cell lung cancer with poor prognosis (TITAN): a randomised ...

T Ciuleanu, I Stelmakh, S Ciceanu, S Miliauskas, AC Grigorescu, ...
The lancet oncology 13 (3), 300-308

ESMO takes a stand on supportive and palliative care

PKMET/SPC/ACG N. I. Cherny, R. Catane
Annals of Oncology 14 (9), 1335–1337

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised ...

AC Grigorescu, IN Draghici, C Nitipir, N Gutulescu, E Corlan
Lung Cancer 37 (1), 9-14

Factors influencing the attitudes and behaviors of oncologists regarding the truthful disclosure of information to patients with advanced and incurable cancer

NIC the Palliative Care Working Group of the European Society for Medical ...
Psycho-Oncology 20, 1269–1284

Recommendation, Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).

elsomino F Tiseo M Barbieri F Riccardi F Cavanna L Frassoldati A Delmonte A ...
Faculty opinions 2020, 10.3410/f.737847695.793574335

Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Buchares
AC Grigorescu
Journal of Translational Internal Medicine 3 (1), 24-28

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea vomiting: Results of the nausea/emesis registry in oncology (NERO)
M Aapro, Z Caprariu, P Chilingirov, M Chrápavá, RO Curca, L Gales, ...
European Journal of Cancer 166, 126-133

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According ...
SS Ramalingam, M Perol, M Reck, RD Kowalyszyn, O Gautschi, ...
Clinical Lung Cancer 19 (3), 270-279. e3

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).
AG Matti S. Aapro, Marika Chrápavá, Razvan-Ovidiu D. Curca, Laurentia Gales
Journal of Clinical Oncology 38 (15), 12083-12083

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).
AWC Matti S. Aapro, Marika Chrápavá, Razvan-Ovidiu D. Curca, Laurentia Gales ...
Journal of Clinical Oncology 38 (15), 411

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive ...
A Grigorescu, T Ciuleanu, E Firoiu, DR Muresan, G Teodorescu, ...
Lung Cancer 57 (2), 168-174

Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small lung cancer patients
AC Grigorescu, C Bala
J BUON 18 (1), 188-194

How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR- mutat NSCLC treatment
C Popescu, L Mazilu, AI Suceveanu, A Grigorescu
Experimental and Therapeutic Medicine 22 (4), 1-5

The importance of the nutritional factor and the stage of the disease in postoperative fistula in patients w gastric cancer
VM Prunoiu, AM Marincas, C Pantis, A Bene, E Bratucu, S Ionescu, ...
Chirurgia 114 (2), 259

Efficacy of second-line erlotinib versus chemotherapy relative to biomarker status in the phase III Globa TITAN Study in advanced non-small-cell lung cancer (NSCLC)
TE Ciuleanu, L Stelmakh, S Cicenias, S Miliuskas, A Grigorescu, ...
JOURNAL OF THORACIC ONCOLOGY 6 (6), S316-S317

B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanc non-small-cell lung cancer (NSCLC)

A Ardizzoni, E Razis, M Lichinitser, U Yilmaz, AC Grigorescu, JL Morero, ...
Journal of Thoracic Oncology 2 (8), S342

Importance of palliative care in medical oncology – the use of IPOS scale

ACG Ciprian Ciobotaru
Oncolog Hematolog 53 (2), 23-26

Tirosyne Kinase Inhibithors (TKIs) in the Treatment of Non–Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects

AC Grigorescu, LM Teodorescu
Journal of Drug Delivery and Therapeutics 10 (1), 135-138

ESMO Guidelines: Cancer patient management during the COVID-19 pandemic

M Aapro, A Addeo, P Acierto, P Balermipas, T Berg, A Berghoff, I Betella, ...

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progression on platinum-based therapy ...

EB Garon, TE Ciuleanu, O Arrieta, K Prabhaskar, KN Syrigos, T Goksel, ...
The Lancet 384 (9944), 665-673

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, resectable small-cell lung cancer with poor prognosis (TITAN): a randomised ...

T Ciuleanu, L Stelmakh, S Cicenias, S Miliauskas, AC Grigorescu, ...
The lancet oncology 13 (3), 300-308

ESMO takes a stand on supportive and palliative care

PKMETSPCACG N. I. Cherny, R. Catane
Annals of Oncology 14 (9), 1335–1337

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised ...

AC Grigorescu, IN Draghici, C Nitipir, N Gutulescu, E Corlan
Lung Cancer 37 (1), 9-14

Factors influencing the attitudes and behaviors of oncologists regarding the truthful disclosure of information to patients with advanced and incurable cancer

NIC the Palliative Care Working Group of the European Society for Medical Oncology
Psycho-Oncology 20, 1269–1284

Recommendation, Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).

elsomino F Tiseo M Barbieri F Riccardi F Cavanna L Frassoldati A Delmonte A ...
Faculty opinions 2020, 10.3410/f.737847695.793574335

Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest

AC Grigorescu
Journal of Translational Internal Medicine 3 (1), 24-28

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO)

M Aapro, Z Caprariu, P Chilingirov, M Chrápavá, RO Curca, L Gales, ...

European Journal of Cancer 166, 126-133

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According ...

SS Ramalingam, M Perol, M Reck, RD Kowalyszyn, O Gautschi, ...
Clinical Lung Cancer 19 (3), 270-279. e3

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).

AG Matti S. Aapro, Marika Chrápavá, Razvan-Ovidiu D. Curca, Laurentia Gales
Journal of Clinical Oncology 38 (15), 12083-12083

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).

AWC Matti S. Aapro, Marika Chrápavá, Razvan-Ovidiu D. Curca, Laurentia Gales ...
Journal of Clinical Oncology 38 (15), 411

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive ...

A Grigorescu, T Ciuleanu, E Firoiu, DR Muresan, G Teodorescu, ...
Lung Cancer 57 (2), 168-174

Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small lung cancer patients

AC Grigorescu, C Bala
J BUON 18 (1), 188-194

How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutate NSCLC treatment

C Popescu, L Mazilu, AI Suceveanu, A Grigorescu
Experimental and Therapeutic Medicine 22 (4), 1-5

The importance of the nutritional factor and the stage of the disease in postoperative fistula in patients with gastric cancer

VM Prunoiu, AM Marincas, C Pantis, A Bene, E Bratucu, S Ionescu, ...
Chirurgia 114 (2), 259

Efficacy of second-line erlotinib versus chemotherapy relative to biomarker status in the phase III Global TITAN Study in advanced non-small-cell lung cancer (NSCLC)

TE Ciuleanu, L Stelmakh, S Cicenias, S Miliauskas, A Grigorescu, ...
JOURNAL OF THORACIC ONCOLOGY 6 (6), S316-S317

B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

A Ardizzoni, E Razis, M Lichinitser, U Yilmaz, AC Grigorescu, JL Morero, ...
Journal of Thoracic Oncology 2 (8), S342

Importance of palliative care in medical oncology – the use of IPOS scale

ACG Ciprian Ciobotaru
Oncolog Hematolog 53 (2), 23-26

Tirosyne Kinase Inhibithors (TKIs) in the Treatment of Non–Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects

AC Grigorescu, LM Teodorescu

Journal of Drug Delivery and Therapeutics 10 (1), 135-138

ESMO Guidelines: Cancer patient management during the COVID-19 pandemic

M Aapro, A Addeo, P Acierto, P Balermipas, T Berg, A Berghoff, I Betella, ...

Immunotherapy in Advanced Lung Cancer Treatment

AC Grigorescu

Lung Cancer-Strategies for Diagnosis and Treatment

Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer

AC Grigorescu

J Integr Oncol 6 (2), 187

Palliative and supportive care in advanced lung cancer.

AC Grigorescu

Oncolog-Hematolog

Long-term survivors in advanced non-small cell lung cancer treated sequentially with cytostatic drugs and erlotinib: A retrospective study

AC Grigorescu

Journal of Translational Internal Medicine 2 (2), 83-86

Blockage of communication with the patient's family-clinical and psycho-emotional implications

VT Grigorean, GR Nita, AM Sandu

Acta Medica Transilvanica 19 (1)

The Hepatitis C Virus E2p7 localization and topology in a recombinant system

C Popescu, A Grigorescu, R Dwek, N Zitzmann

Romanian Journal of Biochemistry 46 (2), 149-63

Platinum-based chemotherapy for patients (PT) with non small cell lung cancer (NSCLC) with anemia treated with eupoetin beta or blood transfusion, a pilot study

AC Grigorescu, C Boldeanu

Annals of Oncology 17, 295-295

The Effects of Oncological Treatment on Redox Balance in Patients with Uveal Melanoma

MA Păsărică, PF Curcă, M Burcea, S Schmitzer, CDM Dragosloveanu, ...

Diagnostics 13 (11), 1907

Real-world evidence with nivolumab in advanced non-small cell lung cancer–second line and beyond. Our experience in Romania following straightaway reimbursement of healthcare ...

M Teodorescu, AC Grigorescu

Oncolog-Hematolog

Cardiac toxicity of checkpoint inhibitors (CPI) used in cancer immunotherapy.

A Grigorescu, M Teodorescu

Oncolog-Hematolog

- Eye malignant melanoma - the correlation of clinical evolution with biological and immunological parameters
ACG Mihai Adrian Pasarica, Cristina Diana Maria Dragosloveanu, Maria Iuliana ...
Oncolog Hematolog 15 (57), 23-31
- Ocular toxicity of biological therapy in solid tumors.
IC Popteanu, M Burcea, A Grigorescu
Oncolog-Hematolog
- Symptom control in patients with advanced lung cancer
AC Grigorescu
Oncolog Hematolog 16 (58), 22-31
- Integrated Palliative Outcome Scale (IPOS) for the early detection of palliative care needs of cancer patients
ACG Ciprian Ciobotaru
Oncolog Hematolog 16 (58), 14-20
- Comparing oxidative metabolism in patients with uveal melanoma versus cutaneous melanoma.
MA Păsărică, PF Curcă, CD Maria Dragosloveanu, V Dinu, M Burcea, ...
Oncolog-Hematolog
- Real-world and clinical trials for assessing the effectiveness of new drugs in oncology. The role of observational studies with exemplification in non-small cell lung cancer ...
M Teodorescu, A Grigorescu
Oncolog-Hematolog
- Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting with Hyphema
MA Păsărică, PF Curcă, CDM Dragosloveanu, CI Tătaru, IR Manole, ...
Diagnostics 12 (6), 1312
- Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting with Hyphema"
GEMACG Mihai Adrian Păsărică 1,2,Paul Filip Curcă 1,2,*ORCID,Christiana ...
Journals Diagnostics 12 (6), 1
- Ethics in clinical research
AC Grigorescu
Oncolog Hematolog 54 (2), 5-8
- Recommendation: IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. Kono M, Yamaki H, Komatsuda H, Kumai T, ..., Takahara M, Katada ...
AC Grigorescu
Faculty Opinions 10 (16)
- Delayed Diagnosis of Clostridium difficile Colitis in a 48-Year-Old Woman with a Homozygous Mutation of the UGT1A1 Gene While on Chemotherapy for Colorectal Carcinoma
AMI Adela Caramoci ORCID logo1ABDEF*, Alexandru Grigorescu2DF, Mirela Pop3ABD
American Journal of Case Reports 23, e934361
- [In Press] Delayed Diagnosis of Clostridium difficile Colitis in a 48-Year-Old Woman with a Homozygous Mutation of the UGT1A1 Gene While on Chemotherapy for Colorectal Carcinoma

AMI Adela Caramoci ORCID logo1ABDEF, Alexandru Grigorescu2DF, Mirela Pop3ABD
American Journal of Case Report 23 (e934361), 1-5

Integrated Palliative Outcome Scale (iPOS) for the early detection of palliative care needs of cancer patients
C Ciobotaru, AC Grigorescu
Oncolog-Hematolog

Recommendation: Efficacy and safety of anti-epidermal growth factor receptor agents for the treatment of oesophageal cancer: a systematic review and meta-analysis.
AC Grigorescu
Faculty Opinions 10 (10.3410/f.739805508.793584158), 10.3410/f.739805508 ...

Some instruments necessary in the practice of palliative care in medical oncology
AC Grigorescu
Oncolog Hematolog 15 (57), 6-11

Ingrijirile paliative in 2021
A Grigorescu
Viata Medicala 1 (3), 64-69

Ingrijirile paliative in 2021
A Grigorescu
Viata Medicala 1 (3), 64-69

Eye malignant melanoma—the correlation of clinical evolution with biological and immunological parameters
MA Păsărică, CD Maria Dragosloveanu, MI Gruia, GE Murgoi, ...
Oncolog-Hematolog

Palliative care present and future
AC Grigorescu
Oncolog Hematolog 56 (3), 32-35

Some Opinions on The Role of The Family Doctor in The Care of Cancer Patients- A Short Review
ACG Catalina Ciocarlan
Biomed J Sci & Tech Res | BJSTR. MS.ID.005255. 3 (1), 12083-12083

Recommendation: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. Li BSkoulidis FFalchook G
AC Grigorescu
Faculty Opinions 10 (10.3410/f.740546305.793587984), 10.3410/f.740546305 ...

Review:"Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy. Wang C, Yang D, Zhang X, Zhang X, ..., Li H ...
AC Grigorescu
Faculty opinions

Recommendation:Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy.
AC Grigorescu
Faculty Opinions 10 (10.3410/f.737935398.793590269), 10.3410/f.737935398 ...

Faculty Opinions Recommendations

A Grigorescu
Faculty Opinions

How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutated NSCLC treatment (Review)

CPLMAISA Grigorescu
EXPERIMENTAL AND THERAPEUTIC MEDICINE 22 (4), 1-5

Recommendation: Preoperative advance care planning for older adults undergoing major abdominal surgery

AC Grigorescu
Faculty Opinions 10 (10.3410/f.740199088.793586396), 10.3410/f.740199088 ...

Correlations between colorectal cancer biomarkers

ACG Alin Radu
Oncolog Hematolog 15 (55), 26-30

Correlations between colorectal cancer biomarkers.

A Radu, AC Grigorescu
Oncolog-Hematolog

Importanța îngrijirilor paliative în oncologia medicală–utilizarea scalei IPOS

C Ciobotaru, A Grigorescu
Oncolog-Hematolog. ro

Breviar terapeutic al cancerului pulmonar fără celule mici, din perspectiva oncologiei medicale

A Grigorescu, C Ciobotaru
Oncolog-Hematolog. ro

Pelvic lymph node dissection in the treatment of cervical and uterine neoplasms-correlation with the histologic type and disease stage

LS Virgil Mihail Prunoiu, Marian Augustin Marincas, Maria Manuela Ravas ...
Oncolog Hematolog 54 (1), 20-24

Brief therapeutic guide to non-small cell lung cancer (NSCLC) from a medical oncology perspective

CC Alexandru C. Grigorescu
Oncolog Hematolog 54 (1), 24-26

Importance of palliative care in medical oncology-the use of IPOSscale

ACG Ciprian Ciobotaru
Oncolog Hematolog 54 (1), 8-10

Chronic Pulmonary Obstructive Disease (COPD) Implications in Lung Cancer Systemic Therapy

AC Grigorescu
EC PULMONOLOGY AND RESPIRATORY MEDICINE 10 (2), 40-43

Review of "Benefits and limitations of a multidisciplinary approach in cancer patient management."

AC Grigorescu
Faculty opinions 2020 (6)

Guide to diagnosis and treatment of breast cancer

SM Alexandru C. Grigorescu
Oncolog Hematolog 52 (3/2020), 8-16

Some Opinions on The Role of The Family Doctor in The Care of Cancer Patients- A Short Review
ACG Catalina Ciocirlan
BJSTR 32 (3), 25028-25030

Systemic Adjuvant Therapy in Non-Small Cell Lung Cancer (NSCLC)
AC Grigorescu
EC PULMONOLOGY AND RESPIRATORY MEDICINE 9 (9), 35-42

Recommendation of "Cancer Therapy & Oncology International Journal"
A Grigorescu
F1000, 10.3410/f.737101363.793569080

Recommendation: "First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost ..."
AC Grigorescu
F1000, 10.3410/f.736170538.793563121

Treatment options for HER2-positive metastatic breast cancer
ACG C. Ciubotaru
Oncolog Hematolog 51 (2), 31-34

Recommendation of "The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis."
AC Grigorescu
Faculty opinions, 10.3410/f.737668835.793573670

Breast cancer treatment and follow-up management during COVID-19 pandemic.
D Luminita Zob, D Lucia Stănculeanu, M Drăgănescu, L Mazilu, C Nitipir, ...
Oncolog-Hematolog

EMERGENCY PALLIATION PROTOCOL FOR NON-VENTILATED COVID-19 PATIENTS – HOMECARE VERSION

[https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19 ...](https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19...)

Introduction to the ESMO COVID-19 Palliative Care Pathways
[https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19 ...](https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19...)

Rules for the manipulation of cytostatic agents used in cancerous disease
AC Grigorescu
Oncolog Hematolog.ro 50 (1), 42-46

Immunotherapy agents combination in metastatic melanoma – case presentation
CC Alexandru C. Grigorescu
Oncolog Hematolog.ro 50 (1), 28-31

Rules for the manipulation of cytostatic agents used in cancerous disease
AC Grigorescu
Oncolog Hematolog 52 (1), 32-36

Rules for the manipulation of cytostatic agents used in cancerous disease

AC Grigorescu

Oncolog Hematolog 50 (1), 42-46

Immunotherapy agents combination in metastatic melanoma-case presentation.

AC Grigorescu, C Ciobotaru

Oncolog-Hematolog

Palliative care for end-of-life stage in oncologic disease

AG Lucian Miron

Oncolog Hematolog 45 (4), 27-30

How to Integrate Medical Oncology and Palliative Care?

ACGTL Mihaela2

EC PULMONOLOGY AND RESPIRATORY MEDICINE 8, 29-31

National screening for cervical cancer. Preliminary experience for breast cancer screening

MMR V.M. Prunoiu¹, Oana Șaptefrați², Rossana Iuliana Brătucu³, Cristina ...

Oncolog Hematolog 13 (49), 27-32

National screening for cervical cancer. Preliminary experience for breast cancer screening.

VM Prunoiu, O Șaptefrați, RI Brătucu, C Șaptefrați, E Brătucu, ...

Oncolog-Hematolog

Short review of immunotherapy with PD-1/PD-L1 inhibitors in non-small-cell lung cancer (NSCLC)

ACG Mihaela Albu

Oncolog Hematolog 46 (1)

Recommendation: "Effect of intensivist involvement on clinical outcomes in patients with advanced lung cancer admitted to the intensive care unit."

AC Grigorescu

F1000, 10.3410/f.735088946.793557239

Importance of nutritional screening in the surgical oncology patient.

VM Prunoiu, AM Marincaș, C Pantiș, A Bene, E Brătucu, A Grigorescu, ...

Oncolog-Hematolog

Difficulties of clinical research in Romania

AC Grigorescu

Oncolog Hematolog 45 (4), 2

Recommendation: "First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer."

GA Calin

F1000, 10.3410/f.734066997.793553700

Targeted therapy in cancer

AC Grigorescu

Oncolog Hematolog 44 (3), 20-22

Immunotherapy of particular cancer localizations – a short review

AC Grigorescu
Oncolog Hematolog 44 (3), 23-25

Imunoterapia in cancer
AC Grigorescu
Viata Medicala 1 (1), 57-61

Palliative care for end-of-life stage in oncologic disease.
L Miron, A Grigorescu
Oncolog-Hematolog

Terapia tintita a cancerului
AC Grigorescu
Viata Medicala 1 (1), 54-61

Imunoterapia cancerului
AC Grigorescu
Viata Medicala 1 (1), 56-61

Recommendation: Gefitinib for advanced non-small cell lung cancer.
AC Grigorescu
F1000, 10.3410/f.732499623.793542180

Recommendation: Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer results from the Italian cohort of an expanded access programme.
AC Grigorescu
F1000, 10.3410/f.733652114.793548529

Recommendatio: "Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer results from the Italian cohort of an expanded access programme."
AC Grigorescu
F1000, 10.3410/f.733652114.793548529

Terapia tintita a cancerului
G alexandru calin
Viata Medicala 1 (1), 54-61

CDK inhibitors and PARP inhibitors in current clinical practice.
AC Grigorescu
Oncolog-Hematolog

Fatigabilitatea în cancer-diagnostic și tratament
A Grigorescu
Oncolog-Hematolog. ro

Carcinom renal cu celule clare-evoluția bolii metastatice și supraviețuirea după patru linii de terapie țintită
Prezentare de caz
A Lăzescu, L Ciurea, I Burlănescu, D Mitulescu, A Grigorescu
Oncolog-Hematolog. ro

Recommendation: Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.

AC Grigorescu
F1000, 10.3410/f.731932336.793537702

Cancer fatigue-diagnosis and treatment.

AC Grigorescu
Oncolog-Hematolog

Clear cell renal carcinoma-evolution of metastatic disease and overall survival after four lines of targeted therapy. Case report.

A Lăzescu, L Ciurea, I Burlănescu, D Mitulescu, A Grigorescu
Oncolog-Hematolog

Squamous cell carcinoma of the lung

AC Grigorescu
Oncolog Hematolog 36 (3), 42-44

Lung cell immunotherapy.

AC Grigorescu
Oncolog-Hematolog

Managing advanced EGFR-positive NSCLC - a short review

AC Grigorescu
Oncolog Hematolog 39 (2), 6-8

Managementul cancerului pulmonar fără celule mici avansat, cu mutație EGFR-scurt review

A Grigorescu
Oncolog-Hematolog. ro

NSCLC with thyroid and parotid metastases at diagnostic, with complete remission after treatment. Case presentation

ACG Dan Ilie-Damboiu
Oncolog Hematolog 34 (1), 36-39

Cancer pulmonar non-microcelular cu metastaze tiroidiene și de parotidă la diagnostic și remisiune completă după tratament. Prezentare

D Ilie-Damboiu, A Grigorescu
Oncolog-Hematolog. ro

The integration of supportive and palliative care with medical oncology.

AC Grigorescu
Oncolog-Hematolog

Updates in the management of advanced NSCLC.

AC Grigorescu
Oncolog-Hematolog

Recommendation: Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.

AC Grigorescu
faculty 1000, 10.3410/f.727384532.793529716

Recommendation: Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.

alexandru C Grigorescu

F1000, 10.3410/f.727384522.793529715

Anal canal cancer diagnosis and treatment aspects

ȘM Laurențiu Simion, Alexandru C. Grigorescu, Angela Mădălina Lazăr

Oncolog Hematolog 34 (1), 20-23

Cancerul de canal anal-aspecte legate de diagnostic și tratament

L Simion, A Grigorescu, AM Lazăr, Ș Marinescu

Oncolog-Hematolog. ro

Rolul radioterapiei în controlul durerii la pacienții cu cancer osos/metastaze osoase

A Grigorescu, V POROH, M Boancă

Oncolog-Hematolog. ro

Pancreatic cancer.

AC Grigorescu

Oncolog-Hematolog

P2. 03a-066 Pemetrexed (P) in Third and Fourth Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (Non-Squamous)-aNSCLCs: Topic: Clinical Trials

AC Grigorescu, D Ilie

Journal of Thoracic Oncology 12 (1), S929

Biosimilars

AC Grigorescu

Oncolog Hematolog 36 (1), 7-9

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

AC Grigorescu

Faculty opinions

Recommendation: Small cell lung cancer in never-smokers.

AC Grigorescu

F1000, 10.3410/f.726037574.793512779

Recommendation: KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.

AC Grigorescu

Faculty 1000, 10.4238/2014.May.9.15

Challenges in the neoadjuvant/adjuvant multimodal treatment in locally advanced rectal tumors. Case report

DL Stănculeanu, D Zob, R Mihăilă, M Alecu, AD Straja, D Mosoiu, ...

Oncolog-Hematolog

Biosimilars

AC Grigorescu

Oncolog Hematolog 22 (2/2016), 7-9

The role of radiotherapy in controlling pain in patients with bone cancer/bone metastasis.
M Boancă, A Grigorescu, V Poroch
Oncolog-Hematolog

recommendation:Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

alexandru C. Grigorescu
F1000, 10.3410/f.727384532.793529716

Anal canal cancer diagnosis and treatment aspects.
Ș Marinescu, AM Lazăr, L Simion, AC Grigorescu
Oncolog-Hematolog

with thyroid and parotid metastases at diagnostic, with complete remission after treatment. Case presentation
D Ilie-Damboiu, AC Grigorescu
Oncolog-Hematolog

Citostatice folosite în cancerele din sfera ginecologică și managementul reacțiilor adverse induse de aceste
A Grigorescu
Oncolog-Hematolog. ro

Recommendation: Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.

alexandru C. Grigorescu
F1000, 10.3410/f.725853745.793510697

Cele mai importante toxicități ale chimioterapicelor folosite în tratamentul tumorilor solide
A Grigorescu
Oncolog-Hematolog. ro

Recommendation: A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy ...

AC Grigorescu
Faculty 1000, 10.3410/f.725638359.793508418

Recommendation: Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.

AC Grigorescu
F1000, <https://doi.org/10.1200/JCO.2012.47.3983>

Main toxicity of chemotherapy for solid tumors.
A Grigorescu
Oncolog-Hematolog

Recommendation: Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.

AC Grigorescu
F1000, 10.3410/f.725276323.793502639

Carcinomul nazofaringial avansat și evoluția cu tratamentul medical
A Grigorescu, C Pentcu

Oncolog-Hematolog. ro

Advanced nasopharyngeal carcinoma with emphases to medical treatment

CP Alexandru C. Grigorescu

Oncolog Hematolog 31 (2), 26-28

Recommendation: A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research ...

AC Grigorescu

F1000, 10.3410/f.725504398.793506877

Actualitati in cancerul ovarian

AC Grigorescu

Oncolog-Hematolog.ro 22 (1), 30-33

Chemotherapy for elderly patients with advanced cancer.

AC Grigorescu

Oncolog-Hematolog

recommendation: Randomized open-label non-comparative multicenter phase II trial of sequential erlotinil and docetaxel versus docetaxel alone in patients with non-small-cell ...

AC Grigorescu

F1000, 10.3410/f.718516697.793498249

Recommendation: 10.3410/f.718163663.793491857

AC grigorescu

F1000, 10.3410/f.718258092.793490636

recommendation: A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer.

AC Grigorescu

F1000, 10.3410/f.719990932.793500891

Key Interventions of Palliative Cancer Care (Ki-Pcc)-Patient Perceived Need and Remembered Delivery E Health-Care Professionals (Hcp): a Prospective, Longitudinal, Multicenter ...

N Magaya-Kalbermatten, P Achimas-Cadariu, R Curca, A Grigorescu, ...

Annals of Oncology 25, iv474

Recommendation: Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.

AC grigorescu

F1000, 10.3410/f.718315380.793493332

recommendation: EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced ...

AC Grigorescu

F1000, 10.3410/f.718505411.793498028

Recommendation: A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.

AC grigorescu

F1000, 10.3410/f.718163663.793491857

BLOCAREA COMUNICĂRII CU FAMILIA PACIENTULUI-IMPLICATII CLINICE ȘI PSIHO-EMOTIONALE.

V TITUS GRIGOREAN, GR NIȚĂ, AM SANDU, A GRIGORESCU, ...
Acta Medica Transilvanica 19 (1)

Recommendation: A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

AC grigorescu
F1000, 10.3410/f.718415927.793495708

Recommendation: Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker ...

AC grigorescu
F1000, 10.3410/f.718389158.793495548

Recommendation: No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy.

alexandru C. Grigorescu
F1000, 10.3410/f.718140888.793489232

Romanian-Swiss Research Program IZERZO: Protocol Development of the "Reality Map of Integrated Oncology and Palliative Care (PC) in Romanian Cancer Centres": Abstract number: PO169

N Magaya-Kalbermatten, P Achimas-Cadariu, R Curca, A Grigorescu, ...
Palliative Medicine. 889 28 (6), 889

Recommendation: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label ...

AC grigorescu
F1000, 10.3410/f.718106825.793486609

Chemotherapy for senior adults with advanced cancer, experience of medical oncology department of institute of oncology Bucharest, a pilot study

AC Grigorescu, SE Boeru
Journal of geriatric oncology 4, S53-S54

Recommendation: Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property. [version 1; peer review: 2 approved]

AC Grigorescu
F1000, 10.3410/f.718106504.793483715

Recommendation: Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded ...

AC Grigorescu
F1000, 10.3410/f.718026266.793481159

Cancerul vezicii urinare.

AC Grigorescu
Oncolog-Hematolog

Actualități în cancerul ovarian. (Russian)

A Grigorescu
Oncolog Hematolog 6 (22), 30-33

Actualități în cancerul ovarian.

AC Grigorescu
Oncolog-Hematolog

Actualitati in cancerul ovarian

AC Grigorescu
Oncolog Hematolog 22 (1/2013), 30-32

CANCERUL TESTICULAR: DIAGNOSTIC și TRATAMENT TESTICULAR CANCER: DIAGNOSIS AND TREATMENT

A Grigorescu
Romanian Journal of Oncology & Hematology 1 (1), 35-38

Erlotinib in Second and Third Line Therapy in Advanced NSCLC (Stage IIIB and IV), Relation with Chemotherapy and Schedule of Administration (A Retrospective Study)

A Grigorescu, I Turtoi, SE Boeru
Annals of Oncology 23, ix398

9127 POSTER Phase II Study of Eriotinib Plus Gemcitabine in First Line Treatment of Poor Prognosis (ECOG PS 2) Advanced Non-small Cell Lung Cancer Patients

A Grigorescu
European Journal of Cancer, S631

Noi tendinte in terapia cancerului mamar

A Grigorescu
Oncolog Hematolog 11 (2), 28-30

Actualitati terapeutice in cancerul bronhopulmonar cu celule mici

AC Grigorescu
Oncolog Hematolog 9 (4), 16-19

Actualitati in cancerul gastric avansat

AC Grigorescu
Oncolog Hematolog 7 (2), 12=13

Integrarea Oncologiei Medicale cu ingrijirile paliative

AC Grigorescu
Hipocrate 3 (30), 56-59

GHID*) din 16 septembrie 2010

C de Traducere, C Aldea, R Anghel, T Ciuleanu, A Croitoru, Ș Curascu, ...
Revista oficială a Societății Europene de Oncologie Medicală și a societății ...

MINISTERUL SĂNĂTĂȚII

C de Traducere, C Aldea, R Anghel, T Ciuleanu, A Croitoru, Ș Curascu, ...
Revista oficială a Societății Europene de Oncologie Medicală și a societății ...

Cseke Attila

C de Traducere, C Aldea, R Anghel, T Ciuleanu, A Croitoru, Ș Curascu, ...
Revista oficială a Societății Europene de Oncologie Medicală și a societății ...

Recomandările Societății Europene de Oncologie Medicală (ESMO) pentru diagnosticul, tratamentul și urmărirea post terapeutică, în afecțiunile oncologice.

O Medicală, C de Traducere, C Aldea, R Anghel, T Ciuleanu, A Croitoru, ...
Revista oficială a Societății Europene de Oncologie Medicală și a societății ...

Ghid din 16/09/2010 Publicat in Monitorul Oficial, Partea I nr. 723bis din 29/10/2010

RSE de Oncologie Medicală, O Medicală, C de Traducere, C Aldea, ...
Revista oficială a Societății Europene de Oncologie Medicală și a societății ...

GEMCITABINE PLUS CARBOPLATIN VERSUS TAXANS PLUS CARBOBLATIN, IN NON SMALL CELL LUNG CANCER, A RETROSPECTIVE OBSERVATIONAL STUDY

A Grigorescu
ANNALS OF ONCOLOGY 19, 120-120

Comparison between antiemetic strategies for hyperemesis induced by antineoplastic chemotherapy, the role of nursing assistance

S Boeru, A Grigorescu
EJC SUPPLEMENTS 3 (2), 447-447

5 Brachytherapy plus chemotherapy in advanced non small cell lung cancer (NSCLC) phase II trial

A Grigorescu, X Bacinschi, S Radoi, V Ciocaltei
Lung Cancer, S380

Prognostic factors for treatment outcome in advanced non-small-cell lung cancer (NSCLC): retrospective study and preliminary results

AC Grigorescu, B Dinu, C Boldeanu
ANNALS OF ONCOLOGY 16, 307-308

P382 A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of ...

G Teodorescu, T Ciuleanu, A Grigorescu, E Firoiu, DR Muresan
Lung Cancer, S271

Brachytherapy plus chemotherapy in advanced non-small cell lung cancer (NSCLC), Pilot study

AC Grigorescu, X Bacinschi, V Ciocaltei, S Radoi, C Bala
ANNALS OF ONCOLOGY 15, 193-193

Celecoxib associated to chemotherapy in non small cell lung cancer (NSCLC), pilot study, intermediary analysis

AC Grigorescu, B Dinu
ANNALS OF ONCOLOGY 15, 181-181

60 Correlation between overall survival and some characteristics of long survivors with advanced non small cell lung cancer (NSCLC) stages (IIIB and IV), a retrospective study

AC Grigorescu, C Bala, I Popa, N Gutulescu
Lung Cancer, S288

P-524 Sequential combination of gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of stage III and IV non ...

T Ciuleanu, E Firoiu, AC Grigorescu, DR Muresan, C Davidescu, ...
Lung Cancer, S224

Chimioterapia cu Gemcitabina si Carboplatin, fata de Cisplatin si Vinblastin in cancerul bronhopulmonar celule mici avansat, stadiul III si IV, studiu clinic controlat fe ...
EC Alexandru Grigorescu, Niculina Draghici, Cornelia Nitipir, Nicolae Gutulescu
InfoMedica 9, 40-45

Gemcitabine plus carboplatin (Gcarb) versus cisplatin plus vinblastine (CV) in patients (pts) with stage II and IV non-small cell lung cancer (NSCLC)
AC Grigorescu, IN Draghici, N Gutulescu, E Corlan
European Journal of Cancer, S21

Gemcitabine plus carboplatin (GCB) versus cisplatin plus vinblastin (CV) in stage IIIB-IV non-small cell lung cancer (NSCLC).
AC Grigorescu, NI Draghici, N Gutulescu
ANNALS OF ONCOLOGY 11, 110-110

Nonmorphinic analgesic combinations in pain treatment for cancer
L Omet, AC Grigorescu
European Journal of Cancer 35, S31-S31

Screeningul național pentru cancerul de col uterin. Experiență preliminară pentru screeningul cancerului sân
VM Prunoiu, O Șaptefrați, RI Brătucu, C Șaptefrați, E Bratucu, ...

Evidarea obturatorie în neoplasmle cervico-uterine corelație în funcție de forma histologică și de stadiu bolii
VM Prunoiu, MA Marinceaș, MM Răvaș, L Iordache, E Bratucu, ...

Short Review of Phase II Study of Erlotinib Plus Gemcitabine in First-Line Treatment of Poor Prognosis Advanced Non-Small Cell Lung Cancer (NSCLC) Patients-8 Years Letter
AC Grigorescu
World Journal of Research and Review 2 (5), 262965

Main original contributions

1. The first global study of phase III published that compare combinations of chemotherapy: Gemzar plus carboplatin compared to cisplatin plus vinblastine. - Confirmed editorial Professor Maurizio Tonato-Lung Cancer 2002 - Chapter III.2.
2. The first study in Romania on endobronchial brachytherapy associated with chemotherapy - Contract Viasan 048 of 30 October 2001 - Chapter XIV
3. The first book in Romania on good clinical practice in clinical trials in oncology. Life Review in SANATATEA, Prof. Dr. Eduard Bild-Chapter V.1
4. The first study reporting cases by Internet of Institute of Oncology Bucharest

5. Representative of Romania and founding member of "ESMO-Central Eastern European Task Force" - 1996 -2006
6. The first representative of Romania in the European Society of Medical Oncology 1999
7. First Romanian representative the International Society of Geriatric Oncology: SIOG.
8. The first representative of Romania and founding member of the Group for palliative care ESMO: ESMO-PCWG.
9. The first member of Romania in geriatric oncology group study of the EORTC (European Organization for Research and Treatment of Cancer).
10. Organizing the first international course in medical oncology in the Institute of Oncology Bucharest.
11. Bronchology Cabinet Organization of Institute of Oncology Bucharest.
12. The first medical oncologist who has acquired expertise in bronchology in Romania.
13. Publication of the first book in palliative care with an international team of authors at the Institute of Oncology Bucharest.
14. Founding member of "Central Eastern European Oncology Group"
15. The first research grant under the European Society of Medical Oncology achieved. in Institute of Oncology Bucharest
16. Obtaining the Diploma of ESMO for Institute of Oncology Bucharest (IOB) like ESMO Designated Center for integration of Medical Oncology with Palliative Care.

Alexandru Calin Grigorescu

02.04 .2026